HB1643

Missouri HB1643 modifies provisions for alternative therapies, including psilocybin, for therapeutic use.

Missouri HB1643 modifies provisions for alternative therapies, including psilocybin, for therapeutic use. It prohibits Medicare certification based solely on a health care provider's recommendation for an investigational drug, biological product, or device. It also shields health care providers from liability for providing care to patients using psilocybin for therapeutic purposes, provided certain conditions are met. The bill defines terms such as "eligible patient" and "bona fide prescriber-patient relationship" and outlines the requirements for patients to use psilocybin therapeutically.